Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 2924-2937

  Cohen, Stanley ^a   Radominski, Sebastião C ^b   Gomez Reino, Juan J ^c   Wang, Lisy ^d   Krishnaswami, Sriram ^d   Wood, Susan P ^d   Soma, Koshika ^d   Nduaka, Chudi I ^d   Kwok, Kenneth ^d   Valdez, Hernan ^d   Benda, Birgitta ^d   Riese, Richard ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Instituto de Salud Carlos III   (Spain)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TOFACITINIB; ANTIRHEUMATIC AGENT; METHOTREXATE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

AGE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BRONCHITIS; CELLULITIS; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DECUBITUS; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; HEPATITIS; HERPES ZOSTER; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; INFLUENZA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MENINGITIS; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SKIN INFECTION; SOFT TISSUE INFECTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIREMIA; VIRUS ENCEPHALITIS; ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; FEMALE; IMMUNOLOGY; INFECTION; LONGITUDINAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFECTION; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921358035     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38779     Document Type: Article

References (44)

1. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al., Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
2. Sokka T, Abelson B, Pincus T,. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26: S35-61.
3. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE,. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
5. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al., Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380-6.
6. Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, et al., Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001; 28: 1163-9.
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al., Risk of herpes zoster in patients with rheumatoid arthritis following tofacitinib therapy. Arthritis Rheumatol 2014; 66: 2675-84.
9. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al., Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
10. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al., Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011; 50: 196-203.
11. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 1125-33.
12. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
13. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, et al., Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8: 266-73.
14. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
15. Van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann RM, Furst DE, et al., Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496-502.
16. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF,. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 13: R141.
17. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al., Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-94.
18. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, et al., Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011; 10: 289-300.
19. Lacaille D, Smitten A, Simon T, Qi K, Franklin J, Askling J, et al., Hospitalized infections in the Abatacept Rheumatoid Arthritis Clinical Development Program: an epidemiological assessment with >10,000 person-years of exposure [abstract]. J Rheumatol 2009; 36: 2568.
20. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al., Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis 2011; 70: 2003-7.
21. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, et al., Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2013. E-pub ahead of print.
22. Ahadieh S, Checchio T, Tensfeldt T, French J, Krishnaswami S, Riese R, et al., Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib and biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum 2012; 64 Suppl: S726.
23. Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al., TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011; 90: 139-45.
24. Listing J, Gerhold K, Zink A,. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52: 53-61.
25. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al., Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
26. Rigby WF, Takiya L, Wood SP, Fan H, Jones TV,. Assessment of lipid changes and infection risk in diabetic and nondiabetic patients with rheumatoid arthritis treated with tofacitinib [abstract]. Arthritis Rheum 2013; 65 Suppl: S995.
27. Malmgaard L,. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004; 24: 439-54.
28. American College of Rheumatology. Update on Herpes zoster (shingles) vaccine for autoimmune disease patients. September 2012. URL: http://www.rheumatology.org/Publications/Hotline/Update-on-Herpes-Zoster-(Shingles)-Vaccine-for-Autoimmune-Disease-Patients/.
29. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al., Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
30. Wolfe F, Michaud K, Anderson J, Urbansky K,. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9.
31. Brassard P, Kezouh A, Suissa S,. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-22.
32. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al., Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 1436-9.
33. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al, on behalf of the BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
34. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al., Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 706-11.
35. Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al., Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006; 65: 1661-3.
36. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al, on behalf of the BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
37. Baldin B, Dozol A, Spreux A, Chichmanian RM,. Tuberculosis and infliximab treatment: national surveillance from January 1, 2000, through June 30, 2003. Presse Med 2005; 34: 353-7. In French.
38. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D,. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-32.
39. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al., The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-206.
40. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP,. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517-24.
41. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, et al., Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013; 40: 1487-97.
42. Mariette X, Gottenberg JE, Ravaud P, Combe B,. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011; 50: 222-9.
43. Galloway JB, Low AS, Mercer LK, Dixon WG, Ustianowski A, Lunt M, et al, British Society for Rheumatology Biologics Register (BSRBR). Opportunistic infections in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register [abstract]. Arthritis Rheum 2011; 63 Suppl: S988.
44. Simard JF, Neovius M, Askling J, for the ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 2012; 64: 3502-10.